mirna microarray system labeling kit  (Illumina Inc)

Journal: Investigative and Clinical Urology

Article Title: Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

doi: 10.4111/icu.20200488

Figure Lengend Snippet: Overview of the study. Twelve candidate miRNAs were identified in the screening cohort (11 up-regulated miRNAs and one down-regulated miRNA in PCa). For ratio analysis, the expression levels of 11 up-regulated miRNAs were compared with that of miR-3659 as the down-regulated miRNA. The diagnostic validity of 11 miRNA ratios was evaluated in the training cohort, and two miRNA ratios (miR-1913 to miR-3659 and miR-20b-3p to miR-3659) were selected for further analysis. In the validation cohort, only the expression ratio of urinary miR-1913 to miR-3659 showed a significant difference between PCa patients and BPH controls. BPH, benign prostate hyperplasia; PCa, prostate cancer; RT-PCR, real-time polymerase chain reaction. a :Candidate showed higher expression in PCa. b :Candidate showed lower expression in PCa or similar expression in PCa and BPH. c :miRNA microarray-based cohort. d :RT-PCRbased cohorts.

Article Snippet: Total RNA was extracted from each sample using the miRNA Microarray System labeling kit (Illumina, San Diego, CA, USA), and RNA quantity and integrity were assessed using the RNA 6000 Pico Chip Kit (Agilent Technologies, Santa Clara, CA, USA) and the Agilent 2100 Bioanalyzer. miRNA profiling was performed using the Agilent Human miRNA Microarray Release 16.0 platform, which contains 1,205 human and 144 viral miRNAs [ ].

Techniques: Expressing, Diagnostic Assay, Biomarker Discovery, Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction, Microarray

Journal: Investigative and Clinical Urology

Article Title: Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

doi: 10.4111/icu.20200488

Figure Lengend Snippet: The microarray data of 12 miRNA candidates

Article Snippet: Total RNA was extracted from each sample using the miRNA Microarray System labeling kit (Illumina, San Diego, CA, USA), and RNA quantity and integrity were assessed using the RNA 6000 Pico Chip Kit (Agilent Technologies, Santa Clara, CA, USA) and the Agilent 2100 Bioanalyzer. miRNA profiling was performed using the Agilent Human miRNA Microarray Release 16.0 platform, which contains 1,205 human and 144 viral miRNAs [ ].

Techniques: Microarray

Journal: Investigative and Clinical Urology

Article Title: Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

doi: 10.4111/icu.20200488

Figure Lengend Snippet: The expression ratio of 11 urinary miRNA ratios (start left top: miR-101-3p, miR-183-3p, miR-1913, miR-20b-3p, miR-200c-3p, miR-3938, miR-452-3p, miR-452-5p, miR-4261, miR-615-3p, miR-643 to miR-3659) in the training cohort. Two urinary miRNA ratios; miR-1913 to miR-3659 and miR-20b-3p to miR-3659, showed significant differences between PCa patients and BPH controls. BPH, benign prostate hyperplasia; PCa, prostate cancer. A p-value was determined by the Mann–Whitney U-test. * p<0.05.

Article Snippet: Total RNA was extracted from each sample using the miRNA Microarray System labeling kit (Illumina, San Diego, CA, USA), and RNA quantity and integrity were assessed using the RNA 6000 Pico Chip Kit (Agilent Technologies, Santa Clara, CA, USA) and the Agilent 2100 Bioanalyzer. miRNA profiling was performed using the Agilent Human miRNA Microarray Release 16.0 platform, which contains 1,205 human and 144 viral miRNAs [ ].

Techniques: Expressing, MANN-WHITNEY